XY Capital Ltd Makes New $673,000 Investment in HUTCHMED (China) Limited (NASDAQ:HCM)

XY Capital Ltd acquired a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 46,676 shares of the company’s stock, valued at approximately $673,000. HUTCHMED comprises 0.3% of XY Capital Ltd’s portfolio, making the stock its 22nd largest holding.

Several other institutional investors also recently made changes to their positions in HCM. Jane Street Group LLC raised its holdings in HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after buying an additional 49,366 shares during the period. State Street Corp increased its stake in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after buying an additional 3,078 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock valued at $268,000 after purchasing an additional 1,799 shares in the last quarter. M&G PLC raised its stake in HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after buying an additional 132,333 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares during the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Stock Performance

Shares of HCM opened at $13.24 on Monday. HUTCHMED has a 52-week low of $13.00 and a 52-week high of $21.92. The firm has a 50-day moving average price of $14.78 and a 200 day moving average price of $17.17. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

HUTCHMED Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.